These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 890970)

  • 1. Hypocholesterolaemia in the rat after p-chlorophenoxyisobutyric acid (CPIB) administration as a synthetic triglyceride, 1,3-dipalmitoyl 2(p-chlorophenoxyisobutyroyl)-rac-glycerol.
    Owen JS; Billimoria JD
    Clin Chim Acta; 1977 Sep; 79(2):349-56. PubMed ID: 890970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of hypocholesterolemic activity for cyclic analogs of clofibrate in normolipemic rats.
    Goldberg AP; Mellon WS; Witiak DT; Feller DR
    Atherosclerosis; 1977 May; 27(1):15-25. PubMed ID: 857813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of hepatic triglyceride formation by clofibrate.
    Adams LL; Webb WW; Fallon HJ
    J Clin Invest; 1971 Nov; 50(11):2339-46. PubMed ID: 5096518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of clofibrate on lipid metabolism in streptozotocin diabetic rats.
    Cayen MN; Dubuc J; Dvornik D
    Proc Soc Exp Biol Med; 1975 Mar; 148(3):752-7. PubMed ID: 165533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clofibrate and clofibric acid: comparison of the metabolic disposition in rats and dogs.
    Cayen MN; Ferdinandi ES; Greselin E; Robinson WT; Dvornik D
    J Pharmacol Exp Ther; 1977 Jan; 200(1):33-43. PubMed ID: 833760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research regarding the action of a derivative of the clofibric acid series on lipid metabolism].
    Filip M; Păduraru I; Hriscu A; Neacşu R; Dănilă G; Filip F
    Rev Med Chir Soc Med Nat Iasi; 1987; 91(2):341-5. PubMed ID: 3685700
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypolipaemic activity of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate) and its analogues in normolipaemic rats.
    Ginocchio AV; Metz G
    Arzneimittelforschung; 1980; 30(11b):2032-4. PubMed ID: 7194054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Action of etofibrate, clofibrate and nicotinic acid on the metabolism of lipids in normolipemic rats. Short term effects and method of action].
    Priego JG; Piña M; Armijo M; Sunkel C; Maroto ML
    Arch Farmacol Toxicol; 1979 Apr; 5(1):29-42. PubMed ID: 38756
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of clofibrate on plasma lipids of rat and rabbit.
    Byers SO; Friedman M
    Atherosclerosis; 1970; 11(3):373-82. PubMed ID: 5433083
    [No Abstract]   [Full Text] [Related]  

  • 10. Anticholesterolemic effect of 3,4-di(OH)-phenylpropionic amides in high-cholesterol fed rats.
    Kim SJ; Bok SH; Lee S; Kim HJ; Lee MK; Park YB; Choi MS
    Toxicol Appl Pharmacol; 2005 Oct; 208(1):29-36. PubMed ID: 16164959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid lowering influence of ethyl p-chlorophenoxyisobutyrate in liver of rats fed high fat diets.
    Kokatnur MG; Malcom GT
    Metabolism; 1970 Feb; 19(2):120-8. PubMed ID: 5410942
    [No Abstract]   [Full Text] [Related]  

  • 12. In vivo and in vitro peroxisome proliferation properties of selected clofibrate analogues in the rat. Structure-activity relationships.
    Esbenshade TA; Kamanna VS; Newman HA; Tortorella V; Witiak DT; Feller DR
    Biochem Pharmacol; 1990 Sep; 40(6):1263-74. PubMed ID: 2403380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of tiadenol, clofibrate and clofibride on bile composition in the rat.
    Rozé C; Cuchet P; Souchard M; Vaille C; Debray C
    Eur J Pharmacol; 1977 May; 43(1):57-64. PubMed ID: 862664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic study and bioavailability of three marketed compounds releasing p-chlorophenoxyisobutyric acid (CPIB) in volunteers.
    Harvengt C; Desager JP
    Int J Clin Pharmacol Biopharm; 1976 Sep; 14(2):113-8. PubMed ID: 1002348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of probucol and clofibrate alone and in combination on hepatic cholesterol metabolism in the male rat.
    Shand JH; West DW
    Biochim Biophys Acta; 1995 Mar; 1255(2):123-30. PubMed ID: 7696326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HYPOLIPEMIA AND HEPATOMEGALY FROM ETHYL CHLOROPHENOXYISOBUTYRATE (CPIB) IN THE RAT.
    BEST MM; DUNCAN CH
    J Lab Clin Med; 1964 Oct; 64():634-42. PubMed ID: 14233152
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of SaH 42-348, an analog of clofibrate, on lipid metabolism in rats.
    Kritchevsky D; Tepper SA
    Arzneimittelforschung; 1973 Jun; 23(6):858-9. PubMed ID: 4740771
    [No Abstract]   [Full Text] [Related]  

  • 18. STUDIES WITH ETHYL CHLOROPHENOXYISOBUTYRATE (CLOFIBRATE).
    AZARNOFF DL; TUCKER DR; BARR GA
    Metabolism; 1965 Sep; 14():959-65. PubMed ID: 14327272
    [No Abstract]   [Full Text] [Related]  

  • 19. Hypocholesterolemic activity of racemic dichlorophenoxypropionic acid or its enantiomers in rats.
    Ohta F; Gaudemer F; Lutton C
    Bull Environ Contam Toxicol; 1987 Dec; 39(6):966-73. PubMed ID: 3440153
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacological study of hydroxy bis-[2-(p-chlorophenoxy)-isobutyric acid] aluminium. I. The effect of hydroxy bis-[2-(p-chlorophenoxy)-isobutyric acid] aluminum on lipid metabolism in normal rats.
    Tomita T; Takeshita R; Nagakura T; Hayashi E
    Jpn J Pharmacol; 1973 Jun; 23(3):281-7. PubMed ID: 4541943
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.